+ +

•  

   

     Western blot analysis using CDH1 mouse mAb against LNCAP (1)?A431 (2), DU145 (3), PC-3 (4), MCF-7 (5), PC-12 (6), NIH/3T3 (7), C6 (8) and COS7 (9) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of Hela cells using CDH1 mouse mAb (green) and negative control (purple).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human gastric cancer tissues (left) and lung cancer tissues (right) using CDH1 mouse mAb with DAB staining.    

  
  

The CDH1 antibody targets the protein E-cadherin, encoded by the *CDH1* gene, a key member of the cadherin superfamily of calcium-dependent cell adhesion molecules. E-cadherin is primarily expressed in epithelial tissues, where it plays a critical role in maintaining cell-cell adhesion, tissue integrity, and polarity. It mediates homophilic interactions between adjacent cells, forming adherens junctions that regulate epithelial morphogenesis and barrier function.

In cancer research, CDH1 is recognized as a tumor suppressor. Loss of E-cadherin expression or function is strongly associated with epithelial-mesenchymal transition (EMT), a process enabling cancer cells to acquire invasive and metastatic properties. CDH1 antibodies are widely used in immunohistochemistry (IHC), Western blot (WB), and immunofluorescence (IF) to assess E-cadherin expression levels in normal versus malignant tissues. Reduced or aberrant E-cadherin staining correlates with poor prognosis in carcinomas, including breast, gastric, and colorectal cancers.

CDH1 mutations are linked to hereditary diffuse gastric cancer (HDGC), making CDH1 antibodies essential tools for diagnosing and studying this syndrome. Additionally, these antibodies aid in investigating EMT mechanisms, drug development targeting metastasis, and understanding developmental biology. Variants like phosphorylated or cleaved forms of E-cadherin may also be detected using specific CDH1 antibodies, providing insights into post-translational regulation and disease pathways.